Loading clinical trials...
Loading clinical trials...
A Phase II Study of the Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
Conditions
Interventions
Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
Meningococcal Polysaccharide groups A, C, W-135 and Y Conjugate Vaccine
Locations
8
Finland
Investigational Site Number 005
Espoo, Finland
Investigational Site Number 006
Helsinki, Finland
Investigational Site Number 002
Helsinki, Finland
Investigational Site Number 007
Jarvenpaa, Finland
Investigational Site Number 008
Oulu, Finland
Investigational Site Number 001
Pori, Finland
Start Date
March 31, 2015
Primary Completion Date
August 19, 2015
Completion Date
August 19, 2015
Last Updated
April 4, 2022
NCT07203755
NCT05590455
NCT05383742
NCT05777499
NCT06811025
NCT06465420
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions